We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.51 | 3.50 | 4.80 | 97,492 | 08:52:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.80 | 10.36M |
TIDMPRM
RNS Number : 0712S
Proteome Sciences PLC
16 December 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) -------------------------------------------------- 1. Identity of the issuer or PROTEOME SCIENCES PLC the underlying issuer of existing shares to which voting rights are attached: (ii) --------------------------------------------------------- --------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): -------------------------------------------------------------------------------------- An acquisition or disposal of voting rights YES ---------------------------------------------------------- -------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ---------------------------------------------------------- -------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ---------------------------------------------------------- -------------------------- An event changing the breakdown of voting rights ---------------------------------------------------------- -------------------------- Other (please specify): -------------------------------------------------------- -------------------------- 3. Full name of person(s) VULPES LIFE SCIENCES FUND subject to the notification obligation: (iii) --------------------------------------------------------- --------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) --------------------------------------------------------- --------------------------- 5. Date of the transaction 14 DECEMBER 2016 and date on which the threshold is crossed or reached: (v) --------------------------------------------------------- --------------------------- 6. Date on which issuer 15 DECEMBER 2016 notified: --------------------------------------------------------- --------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 18% --------------------------------------------------------- --------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of voting % of voting of of of shares rights rights (x) Shares Voting Rights ------------- --------------- --------------- ------------- --------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- ------------- ------------- ------------ ------------ ----------- GB0003104196 36,573,125 36,573,125 52,973,125 52,973,125 18.00% --------------- --------------- ------------- ------------- ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------ ----------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument (xvii) period refers to (xix, xx) (xviii) --------------- ------------- ------------- --------------- ----------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- --------------- ----------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 52,973,125 18.00% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) --------------------------------------------------------------------------------------------- Proxy Voting: --------------------------------------------------------------------------------------------- 10. Name of the proxy holder: -------------------------------------------------------------- ----------------------------- 11. Number of voting rights proxy holder will cease to hold: -------------------------------------------------------------- ----------------------------- 12. Date on which proxy holder will cease to hold voting rights: -------------------------------------------------------------- ----------------------------- executive.pa@proteomics.com 13. Additional information: ------------------------------------------------------------ ------------------------------- 14. Contact name: Victoria Birse ------------------------------------------------------------ ------------------------------- 15. Contact telephone number: ------------------------------------------------------------ ------------------------------- Note: Annex should only be submitted to the FCA not the issuer Annex: Notification of major interests in share A: Identity of the persons or legal entity subject to the notification obligation ----------------------------------------------------------------------- Full name VULPES LIFE SCIENCES FUND (including legal form of legal entities) ------------------------------------ --------------------------------- Contact address c/o Maples Corporate Services (registered office for legal Limited, PO entities) Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands ------------------------------------ --------------------------------- Phone number & email ------------------------------------ --------------------------------- Other useful information (at least legal representative for legal persons) ------------------------------------ --------------------------------- B: Identity of the notifier, if applicable ----------------------------------------------------------------------- Full name Stephen Diggle ------------------------------------ --------------------------------- Contact address One George Street #07-03 Singapore 049145 ------------------------------------ --------------------------------- Phone number & email Tel: (65) 6538 1998 (Main) Email: sdiggle@vulpesinvest.com ------------------------------------ --------------------------------- Other useful information Director (e.g. functional relationship with the person or legal entity subject to the notification obligation)
------------------------------------ --------------------------------- C: Additional information ----------------------------------------------------------------------- Email address: Complete the required TR-1 form and email it to: Major shareholdings majorshareholdings@fca.gov.uk Fax number: You can print the TR-1 form, complete it and fax it to: 020 7066 0050 ----------------------------------------------------------------------- For notes on how to complete form TR-1 please see the FCA website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLGGGAPPUPQUBQ
(END) Dow Jones Newswires
December 16, 2016 04:28 ET (09:28 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions